• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CYCLOSPORINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CYCLOSPORINE chembl:CHEMBL160 ApprovedImmunotherapy

    Alternate Names:

    CAPIMUNE
    CYCLOSPORIN A
    RESTASIS MULTIDOSE
    SANDIMMUN
    SDZ-OXL-400
    VANQUORAL
    RESTASIS
    ANTIBIOTIC S-7481F1
    SANGCYA
    OPTIMMUNE
    27-400
    SANG-35
    CEQUA
    DEXIMUNE
    CICLOSPORIN
    IKERVIS
    SANDIMMUNE
    CYCLOSPORINE
    NEORAL
    OL-27-400
    GENGRAF
    CAPSORIN
    NSC-290193
    30-ETHYL-33-[(4E)-1-HYDROXY-2-METHYLHEX-4-EN-1-YL]-6,9,18,24-TETRAISOBUTYL-3,21-DIISOPROPYL-1,4,7,10,12,15,19,25,28-NONAMETHYL-1,4,7,10,13,16,19,22,25,28,31-UNDECAAZACYCLOTRITRIACONTANE-2,5,8,11,14,17,20,23,26,29,32-UNDECONE
    OLO400
    1,11-CYCLO[L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL-(E)-(2S,3R,4R)-2-AMINO-3-HYDROXY-N,4-DIMETHYLOCT-6-ENOYL-L-2-AMINOBUTANOYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCINE]
    CSA
    CYCLO(L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL-((3R,4R,6E)-6,7-DIDEHYDRO-3-HYDROXY-N,4-DIMETHYL-L-2-AMINOOCTANOYL)-L-2-AMINOBUTANOYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYLLEUCYL)
    ANTIBIOTIC S 7481F1
    (R-[R*,R*-(E)])-CYCLIC(L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL-3-HYDROXY-N,4-DIMETHYL-L-2-AMINO-6-OCTENOYL-L-ALPHA-AMINOBUTYRYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCYL)
    CYCLOSPORINE A
    CYA
    chemidplus:59865-13-3
    chembl:CHEMBL160
    drugbank:00091
    pubchem.compound:5284373
    rxcui:3008

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications immunosuppressant
    Drug Class immunosuppressive agents
    Year of Approval 1983
    (6 More Sources)

    Publications:

    Abdel-Hady Algharably E et al., 2018, Effect of UMOD genotype on long-term graft survival after kidney transplantation in patients treated with cyclosporine-based therapy., Pharmacogenomics J
    Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Wu, From bedside to bench drug-induced tubulointerstitial disease cyclosporine nephropathy study from models of cultured renal epithelial cells., Chang Gung Med J
    Perico et al., 1992, Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft., J. Am. Soc. Nephrol.
    Juvale K et al., 2012, 4-Substituted-2-phenylquinazolines as inhibitors of BCRP., Bioorg Med Chem Lett
    Utsunomiya et al., 2000, Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line., Eur J Nucl Med
    Van Gool et al., 1995, Accessory signalling by B7-1 for T cell activation induced by anti-CD2: evidence for IL-2-independent CTL generation and CsA-resistant cytokine production., Scand. J. Immunol.
    Ma et al., 2002, The role of Ras in T lymphocyte activation., Cell. Signal.
    Toebak et al., 2008, Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs., Br. J. Dermatol.
    Yamashita et al., 2010, Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis., Eur. J. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Cardenas ME et al., 1994, Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands., EMBO J
    Grigoriu S et al., 2013, The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin., PLoS Biol
    Bulut et al., 2004, Immunohistochemical study of cyclosporin-induced gingival overgrowth in renal transplant recipients., J. Periodontol.
    Mueller et al., 1993, The effect of cyclosporine treatment on the expression of genes encoding granzyme A and perforin in the infiltrate of mouse heart transplants., Transplantation
    Bernasconi et al., 2010, Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation., PLoS ONE
    Galat et al., 2010, Molecular aspects of cyclophilins mediating therapeutic actions of their ligands., Cell. Mol. Life Sci.
    Lee et al., 2010, Current implications of cyclophilins in human cancers., J. Exp. Clin. Cancer Res.
    Forsythe P et al., 2014, Ciclosporin 10 years on: indications and efficacy., Vet Rec
    Russell G et al., 1992, Mechanisms of action of cyclosporine and effects on connective tissues., Semin Arthritis Rheum
    Seip et al., 1988, Cyclosporine in steroid-resistant Diamond-Blackfan anaemia., Acta Paediatr Scand
    Cvetković M et al., 2017, Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia., Ther Drug Monit
    Lunde I et al., 2014, The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients., Eur J Clin Pharmacol
    Elens L et al., 2014, Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients., Ther Drug Monit
    Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
    Lou K et al., 2014, Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies., J Med Chem
    Silva GL et al., 2001, Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei., J Nat Prod
    Liu XL et al., 2008, Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein., Bioorg Med Chem
    Condello M et al., 2014, Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts., J Nat Prod
    Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
    Sánchez-Lázaro I et al., 2015, Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation., Pharmacogenomics
    Lee J et al., 2015, The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis., Basic Clin Pharmacol Toxicol
    Sharaki O et al., 2015, Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients., Mol Biol Rep
    Ferraresso M et al., 2013, Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients., Pharmacogenomics
    Barbarino JM et al., 2013, PharmGKB summary: cyclosporine and tacrolimus pathways., Pharmacogenet Genomics
    García M et al., 2013, ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients., Eur J Clin Pharmacol
    Santoro A et al., 2011, Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients., Pharmacogenomics
    Yanagimachi M et al., 2010, Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation., Clin Transplant
    Zhang YT et al., 2008, ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients., Br J Clin Pharmacol
    Beringer PM et al., 2008, Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis., Pharmacotherapy
    Grinyó J et al., 2008, Association of four DNA polymorphisms with acute rejection after kidney transplantation., Transpl Int
    Crettol S et al., 2008, Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients., Pharmacogenet Genomics
    Daniel F et al., 2007, Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis., Inflamm Bowel Dis
    Hesselink DA et al., 2003, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus., Clin Pharmacol Ther
    Herweijer et al., 1990, Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine., J. Natl. Cancer Inst.
    Niederer et al., 2005, Cypermethrin blocks a mitochondria-dependent apoptotic signal initiated by deficient N-linked glycosylation within the endoplasmic reticulum., Cell. Signal.
    Shah S et al., 2012, Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome., Transplantation
    Pazik J et al., 2011, Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism., Transplant Proc
    Winnicki W et al., 2010, An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid., Pharmacogenomics J
    Sombogaard F et al., 2009, Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism., Pharmacogenet Genomics
    Stegmann et al., 2010, The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein., PLoS ONE
    Redell et al., 2007, Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation., J. Neurosci. Res.
    Schaller et al., 2007, Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses., J. Virol.
    Patwardhan et al., 2006, The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin., Proc. Natl. Acad. Sci. U.S.A.
    Keckesova et al., 2006, Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity., J. Virol.
    Hong et al., 2002, Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity., FASEB J.
    Hopkins S et al., 2010, SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro., Antimicrob Agents Chemother
    Grenet et al., 2000, Evidence for the impairment of the vitamin D activation pathway by cyclosporine A., Biochem. Pharmacol.
    Sharma S et al., 2013, Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes., Drug Metab Dispos
    Dianov et al., 1997, Reduced RNA polymerase II transcription in extracts of cockayne syndrome and xeroderma pigmentosum/Cockayne syndrome cells., Nucleic Acids Res.
    Valentine et al., 1997, Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and rapamycin., Int. Immunol.
    Božina N et al., 2017, Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions., Eur J Clin Pharmacol
    Han N et al., 2014, Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients., Eur J Clin Pharmacol
    Yang et al., 2002, Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-kappaB and protein kinase activity., Scand. J. Immunol.
    Cho et al., 2002, Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes., Arthritis Rheum.
    Baan et al., 2001, Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression., Clin Transplant
    Lewis et al., 2001, Interleukin-15 is the main mediator of lymphocyte proliferation in cultures mixed with human kidney tubular epithelial cells., Transplantation
    Akashi et al., Dermatomyositis associated with membranous nephropathy in a 43-year-old female., Am. J. Nephrol.
    Kajita et al., 2006, Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats., J. Pharm. Pharmacol.
    Combes S et al., 2011, Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2., J Med Chem
    Pawarode et al., 2007, Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins., Cancer Chemother. Pharmacol.
    Ling Q et al., 2013, Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population., J Hepatol
    Kurzawski M et al., 2011, Association of transcription factor 7-like 2 (TCF7L2) gene polymorphism with posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus., Pharmacol Rep
    Pette et al., 1997, In vitro modulation of human, autoreactive MBP-specific CD4 + T-cell clones by cyclosporin A., J. Neuroimmunol.
    Kusztal M et al., 2007, Possible association of CTLA-4 gene polymorphism with cyclosporine-induced gingival overgrowth in kidney transplant recipients., Transplant Proc
    Beall et al., 1999, Cyclosporine-induced renal artery smooth muscle contraction is associated with increases in the phosphorylation of specific contractile regulatory proteins., Biochim. Biophys. Acta
    Richter et al., 2003, Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: comparative study with cyclosporine and FK 506., J. Heart Lung Transplant.
    Poston et al., 1999, Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method., Transplantation
    Aoki et al., 1998, CsA-sensitive purine-box transcriptional regulator in bronchial epithelial cells contains NF45, NF90, and Ku., Am. J. Physiol.
    Bianchi et al., 2003, Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart., Int. Immunopharmacol.
    Jin et al., 2004, Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation., Transplantation
    Mampaso et al., 1993, Expression of adhesion molecules in allograft renal dysfunction. A distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity., Transplantation
    Ciesielski et al., 1998, Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts., Transpl. Immunol.
    Pyrzynska et al., 2002, Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A., J. Biol. Chem.
    Gnoatto et al., 2003, Gene expression of extracellular matrix proteoglycans in human cyclosporin-induced gingival overgrowth., J. Periodontol.
    Robida et al., 2000, Cyclosporin A selectively inhibits mitogen-induced cyclooxygenase-2 gene transcription in vascular smooth muscle cells., Mol. Pharmacol.
    Mueller et al., 1990, Indicators of acute renal-transplant rejection in patients treated with cyclosporine., Clin. Chem.
    Woillard JB et al., 2010, Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele., Br J Clin Pharmacol
    Sun B et al., 2017, Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients., Pharmacogenomics
    Liu M et al., 2012, An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases., Bioorg Med Chem Lett
    Chan et al., 1987, Cyclosporine and dexamethasone inhibit T-lymphocyte MHC class II antigens and IL-2 receptor expression in experimental autoimmune uveitis., Immunol. Invest.
    Quteineh L et al., 2017, CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation., Pharmacogenomics J
    Louhelainen et al., 2006, Lipoic acid supplementation prevents cyclosporine-induced hypertension and nephrotoxicity in spontaneously hypertensive rats., J. Hypertens.
    Kurzawski M et al., 2005, The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients., Ther Drug Monit
    Formea CM et al., 2004, Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients., Am J Transplant
    Wuthrich et al., 1993, Effect of dexamethasone, 6-mercaptopurine and cyclosporine A on intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression., Biochem. Pharmacol.
  • CYCLOSPORINE   CAMLG

    Interaction Score: 8.98

    Interaction Types & Directionality:
    binder

    Interaction Info:
    Trial Name Chiron
    Novel drug target Established target
    Trial Name cyclosporine,Restasis

    PMIDs:
    20674565 20927389 20602248 20637127 17016423 17139284 24682697 1502562


    Sources:
    TdgClinicalTrial

  • CYCLOSPORINE   PPP3R2

    Interaction Score: 6.98

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name FOV-1101,Prednisporin
    Trial Name cyclosporine,Restasis
    Novel drug target Established target

    PMIDs:
    20674565 17016423 17139284 7529175 23468591


    Sources:
    TdgClinicalTrial TEND

  • CYCLOSPORINE   PPIA

    Interaction Score: 2.74

    Interaction Types & Directionality:
    binder
    inhibitor (inhibitory)
    modulator

    Interaction Info:
    Mechanism of Interaction Cyclophilin A modulator
    Direct Interaction yes

    PMIDs:
    20368803 17461417 17609268 16849427 16641261 20637127 12207006 19933795


    Sources:
    DTC ChemblInteractions NCI

  • CYCLOSPORINE   VCAN

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14974815


    Sources:
    NCI

  • CYCLOSPORINE   GZMA

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8420038


    Sources:
    NCI

  • CYCLOSPORINE   UMOD

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28418009


    Sources:
    PharmGKB

  • CYCLOSPORINE   ILF3

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9843854


    Sources:
    NCI

  • CYCLOSPORINE   ERCC6

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9278484


    Sources:
    NCI

  • CYCLOSPORINE   IMPDH2

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22960765 21996196 19770842 19617864 18444945


    Sources:
    PharmGKB

  • CYCLOSPORINE   IL15

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11817607 11683823 11571455


    Sources:
    NCI

  • CYCLOSPORINE   GABPA

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16612258


    Sources:
    NCI

  • CYCLOSPORINE   HSPG2

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14974815


    Sources:
    NCI

  • CYCLOSPORINE   TCF7L2

    Interaction Score: 0.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23041303 21857094


    Sources:
    PharmGKB

  • CYCLOSPORINE   VCAM1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7694584


    Sources:
    NCI

  • CYCLOSPORINE   POR

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29135906 24658827 24061445


    Sources:
    PharmGKB

  • CYCLOSPORINE   ICAM3

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15732868


    Sources:
    NCI

  • CYCLOSPORINE   CRTC2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26644205


    Sources:
    PharmGKB

  • CYCLOSPORINE   SAG

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3123380


    Sources:
    NCI

  • CYCLOSPORINE   MBP

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9184637


    Sources:
    NCI

  • CYCLOSPORINE   LOH19CR1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3389144


    Sources:
    NCI

  • CYCLOSPORINE   TPMT

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16044099 15476481


    Sources:
    PharmGKB

  • CYCLOSPORINE   ABCA1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15084924


    Sources:
    NCI

  • CYCLOSPORINE   ABCB4

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1972761


    Sources:
    NCI

  • CYCLOSPORINE   IL5

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9237106


    Sources:
    NCI

  • CYCLOSPORINE   PPP3CA

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CYCLOSPORINE   MUC16

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12169874


    Sources:
    NCI

  • CYCLOSPORINE   CD80

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11841687


    Sources:
    NCI

  • CYCLOSPORINE   ABCB11

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23129211


    Sources:
    DTC

  • CYCLOSPORINE   CCL17

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18028503


    Sources:
    NCI

  • CYCLOSPORINE   HSPB2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10076049


    Sources:
    NCI

  • CYCLOSPORINE   CYP3A7

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28952408


    Sources:
    PharmGKB

  • CYCLOSPORINE   TBXA2R

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1385733


    Sources:
    NCI

  • CYCLOSPORINE   UGT1A8

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20565459


    Sources:
    PharmGKB

  • CYCLOSPORINE   ANPEP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2337986


    Sources:
    NCI

  • CYCLOSPORINE   ITGAL

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14550820 10515383


    Sources:
    NCI

  • CYCLOSPORINE   ITGB2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8212167 9777701


    Sources:
    NCI

  • CYCLOSPORINE   IL10

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18444945


    Sources:
    PharmGKB

  • CYCLOSPORINE   CDKN1A

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11827957


    Sources:
    NCI

  • CYCLOSPORINE   CTLA4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18021981


    Sources:
    PharmGKB

  • CYCLOSPORINE   FCGR3B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17852453


    Sources:
    NCI

  • CYCLOSPORINE   JAK1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22101135


    Sources:
    DTC

  • CYCLOSPORINE   ABCB1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24992153 11754602 17964170 23017888 24720452 21348461 26107754 25536375 25240575 24088131 23922006 22886152 21806386 20030680 18717915 18576903 18444945 18334915 17206635 12966368 1972761


    Sources:
    DTC NCI PharmGKB

  • CYCLOSPORINE   ABCG2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16805961 21488686 17031644


    Sources:
    DTC NCI PharmGKB

  • CYCLOSPORINE   IL2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7529939 12135706


    Sources:
    NCI

  • CYCLOSPORINE   MMP2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12639820


    Sources:
    NCI

  • CYCLOSPORINE   FCGR3A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17852453


    Sources:
    NCI

  • CYCLOSPORINE   ABCC1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23017888 11189941


    Sources:
    DTC NCI

  • CYCLOSPORINE   DDIT3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15494209


    Sources:
    NCI

  • CYCLOSPORINE   ABCC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28624888 25163792


    Sources:
    DTC PharmGKB

  • CYCLOSPORINE   AGTR1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17477024


    Sources:
    NCI

  • CYCLOSPORINE   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18444945


    Sources:
    PharmGKB

  • CYCLOSPORINE   PTGS2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10999939


    Sources:
    NCI

  • CYCLOSPORINE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034


    Sources:
    NCI

  • CYCLOSPORINE   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24088131


    Sources:
    PharmGKB

  • CYCLOSPORINE   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYCLOSPORINE   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10609555


    Sources:
    NCI

  • CYCLOSPORINE   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYCLOSPORINE   ATXN2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYCLOSPORINE   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYCLOSPORINE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYCLOSPORINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CYCLOSPORINE   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CYCLOSPORINE

    • Version: 01-August-2011

    Alternate Names:
    CYCLOSPORINE Primary Drug Name

    Drug Info:
    Year of Approval 1983
    Drug Class immunosuppressive agents

    Publications:

  • TdgClinicalTrial: CYCLOSPORINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications immunosuppressant
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • NCI: CSA

    • Version: 14-September-2017

    Alternate Names:
    C406 NCI drug code

    Drug Info:

    Publications:
    Wu, From bedside to bench drug-induced tubulointerstitial disease cyclosporine nephropathy study from models of cultured renal epithelial cells., Chang Gung Med J
    Utsunomiya et al., 2000, Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line., Eur J Nucl Med
    Niederer et al., 2005, Cypermethrin blocks a mitochondria-dependent apoptotic signal initiated by deficient N-linked glycosylation within the endoplasmic reticulum., Cell. Signal.

  • DTC: CYCLOSPORINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL160 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hopkins S et al., 2010, SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro., Antimicrob Agents Chemother
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Juvale K et al., 2012, 4-Substituted-2-phenylquinazolines as inhibitors of BCRP., Bioorg Med Chem Lett

  • NCI: CYCLOSPORINE

    • Version: 14-September-2017

    Alternate Names:
    C406 NCI drug code

    Drug Info:

    Publications:
    Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
    Herweijer et al., 1990, Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine., J. Natl. Cancer Inst.
    Mueller et al., 1990, Indicators of acute renal-transplant rejection in patients treated with cyclosporine., Clin. Chem.

  • NCI: CICLOSPORIN

    • Version: 14-September-2017

    Alternate Names:
    C406 NCI drug code

    Drug Info:

    Publications:
    Toebak et al., 2008, Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs., Br. J. Dermatol.
    Kajita et al., 2006, Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats., J. Pharm. Pharmacol.
    Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.

  • PharmGKB: cyclosporine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Abdel-Hady Algharably E et al., 2018, Effect of UMOD genotype on long-term graft survival after kidney transplantation in patients treated with cyclosporine-based therapy., Pharmacogenomics J
    Pazik J et al., 2011, Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism., Transplant Proc
    Winnicki W et al., 2010, An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid., Pharmacogenomics J

  • TTD: Cyclosporine

    • Version: 2020.06.01

    Alternate Names:
    D0O3YF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL160

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL160

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21